From: Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool?
Variable (N= 467) | Data |
---|---|
Age at Diagnosis, years | |
Mean and standard deviation | 59 ± 13 |
Range | 64 (Min 28; Max 92) |
Tumour Size (cm) | |
Mean and standard deviation | 3.110 cm ± 2.00 cm |
Range | 15.6 (Min 0.4; max 16) |
T1: < 2 cm | 101 (24.7%) |
T2: 2-5 cm | 245 (59.9%) |
T3: > 5 cm | 63 (15.4%) |
Not assessed | 58 |
Lymph Node Invasion | |
Present | 207 (56.6%) |
Absent | 159 (43.4%) |
Not assessed | 101 |
Histological Grade | |
Grade I | 81 (18.3%) |
Grade II | 135 (30.5%) |
Grade III | 227 (51.2%) |
Not assessed | 24 |
Oestrogen receptor | |
Positive | 309 (66.5%) |
Negative | 156 (33.5%) |
Not assessed | 2 |
Progesterone Receptor | |
Positive | 228 (48.9%) |
Negative | 238 (51.1%) |
Not assessed | 1 |
HER2 | |
Positive | 68 (14.7%) |
Negative | 395 (85.3%) |
Not assessed | 4 |
Nottingham Prognostic Index | |
NPI < 3.4 | 99 (24.4%) |
3.4 ≤ NPI ≤ 5.4 | 188 (46.4%) |
NPI > 5.4 | 118 (29.2%) |
Not assessed | 62 |
Molecular Subtype | |
Luminal | 343 (73.6%) |
HER2 Over-expressing | 33 (7.1%) |
Triple Negative | 90 (19.3%) |